Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

NICE recommends ixekizumab for treatment of severe plaque psoriasis

Eli Lilly and Company have announced that ixekizumab (Taltz) has been recommended by NICE for use as a treatment option within the NHS in England, Wales and Northern Ireland for adults with severe plaque psoriasis who have responded inadequately to standard systemic therapies

Eli Lilly and Company have announced that ixekizumab (Taltz) has been recommended by NICE for use as a treatment option within the NHS in England, Wales and Northern Ireland for adults with severe plaque psoriasis who have responded inadequately to standard systemic therapies. The announcement follows on from NICE’s final Technology Appraisal Guidance (TAG) on the use of ixekizumab, which was published today. The Scottish Medicines Consortium published its guidance on the use of ixekizumab by the NHS in Scotland earlier this month. It is accepted for restricted use within NHS Scotland to treat moderate to severe plaque psoriasis in

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy